World Health Organization forecasts 25% fewer Covid vaccines for the world this year than earlier hoped


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
WHO covid vaccine forecast

The World Health Organization's vaccine-sharing program COVAX forecasts an additional 1.1 billion Covid-19 vaccine doses will be made available globally between now and the end of the year, fewer than previously estimated.

This forecast, released Wednesday, projects 25% fewer doses compared to July's forecast. The new projection prompted a fresh call from WHO for rich countries to hold off on giving boosters until more people around the world can get their first doses of vaccine.


Currently, 330 million doses have been released for delivery to underserved countries through COVAX, and 230 million have been delivered to member countries.


In what the report calls the "most likely scenario" for vaccine supply through the end of the year, more than a billion more doses will be made available between September and the end of the year.


"We expect to have a further 1.1 billion doses available for delivery between now and the end of the year," Dr Seth Berkley, CEO of GAVI, one of the groups that makes up COVAX, said in a media briefing. Doses will be targeted to 92 lower-income countries.

This prediction would put total vaccine availability in all of 2021 at 1.4 billion doses, with 1.2 billion available for low-income countries.The most recent forecast from July predicted 1.8 billion total available vaccines in 2021. The new COVAX analysis cited export restrictions in India, manufacturing issues with AstraZeneca facilities, Novavax regulatory delays, and pending approval of Chinese biopharmaceutical company Clover's vaccine as driving the decline, in addition to production issues with Johnson & Johnson's vaccine.


"Production issues at J&J's Emergent facility (which is assigned to supply COVAX) have led to delays," the report reads. Emergent's Baltimore vaccine plant stopped production for months after a mix-up earlier this year involving ingredients for the J&J and AstraZeneca vaccines.

"While production has now restarted, the manufacturing ramp-up combined with the backlog of orders for other bilateral customers has led to delayed timelines and lower volumes that will be made available to COVAX in 2021."
According to the report, 180 million of the doses lost between the July forecast and the September forecast were to have been supplied by Johnson & Johnson.
The forecast does indicate more doses will be available from two sources: an expected gain of 20 million doses from China's Sinopharm and an additional 95 million doses in the form of donations.


I will not stay silent

WHO Director-General Tedros Adhanom Ghebreyesus reiterated his call for wealthy nations to refrain from boosting their Covid-19 vaccinations until shots are available to more of the world -- this time, asking countries to wait until at least the end of the year, rather than the end of September.

"A month ago, I called for a global moratorium on booster doses, at least until the end of September, to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose. There has been little change in the global situation since then," Tedros said during a media briefing on Wednesday.

"So today, I'm calling for an extension of the moratorium, until at least the end of the year, to enable every country to vaccinate at least 40% of its population."

Tedros acknowledged that third doses may be needed for those most at risk who see their immunity wane, "but for now, we do not want to see widespread use of boosters for healthy people who are fully vaccinated."

Tags : #WHO #WHOVaccineForecast #Covax #Gavi #AstraZeneca #JohnsonandJohnson

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026